Holly McCaleb

Holly is starting her 20th year with Pfizer, the last 13 years of those being in Regulatory CMC. She has experience leading clinical and commercial submissions in multiple types of biologic modalities, including mAbs, ADCs, gene therapies, and bispecifics. Holly has a BS in Biochemistry from the University of Nebraska - Lincoln, an MS in Biochemistry from Texas A&M, and an MS in Bioscience Regulatory Affairs from Johns Hopkins.